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Thyroid Size and Hypothyroidism
in Hashimoto’s Thyroiditis
Balamurugan Pandiyan
Abstract
This chapter is devoted to studying the physiology of the pituitary-thyroid axis
and thyroid size in autoimmune thyroiditis via modeling. The pituitary-thyroid axis
consists of a feed forward and backward loop in humans, which is responsible for
maintaining the body’s metabolism. Under a disease situation, the dynamics of the
axis becomes more complex and unique among patients. Hashimoto’s autoimmune
thyroiditis disrupts the normal operation of the axis by slowly destroying the thy-
roid follicle cells through complex immune mechanisms. So, the size of thyroid and
the axis operation are fully, partly, or totally not functional in this disease. Basically,
the patient situation in the disease process is unique in describing the diffused goiter
and/or a clinical symptom of hashitoxicosis, euthyroidism, subclinical hypothy-
roidism, or overt hypothyroidism. Using patient-specific modeling, we can predict
the hidden dynamics of the natural history of autoimmune thyroiditis and test
hypothesis on the operation of axis. In addition, we unfold case studies of three
patients from the thyroid literature through the modeling viewpoint and describe
their hidden dynamics.
Keywords: Hashimoto’s thyroiditis, chronic lymphocytic thyroiditis, goiter,
hypothyroidism, patient-specific modeling, pituitary-thyroid axis
1. Introduction
The normal operation of the pituitary-thyroid axis depends on the levels of
thyroid stimulating hormone (TSH) and thyroid hormones, triiodothyronine (T3)
and thyroxine (T4) [1]. Serum TSH is produced and released by the pituitary gland
in response to the low levels of free thyroid hormones in the serum. Circulating TSH
in turn stimulates the thyroid to produce and secrete T3 and T4 into the serum.
When thyroid hormones reach their highest levels, it inhibits the production of
TSH, which describes the normal day to day operation of the pituitary-thyroid axis.
The axis is commonly referred as an important negative feedback loop in the
endocrine system. The normal function of this loop is essential for the body’s
metabolic rate—it affects how quickly the cells in our body use the energy stored
within itself [2, 3]. For the purpose of this modeling work, we use only serum free
T4 for the levels of thyroid hormones as frequently asked to measure in the thyroid
clinics for all patients with Hashimoto’s autoimmune thyroiditis (see Figure 1).
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The normal operation of the axis can be tested and verified clinically via one
measurement of TSH and free T4 from the blood serum. Laboratory tests are
important in diagnosing conditions of the thyroid gland [2]. The result of the blood
test is determined approximately based on the normal reference range of TSH and
free T4 is (0.4–4) mU/L and (7–18) pg/mL, respectively as recommended by the
American Thyroid Association [2]. As the physiology of the axis is governed by TSH
and free T4, the clinical state of the axis has been defined based on these values [3].
Suppose TSH and free T4 levels falls within the normal reference range; the state of
the axis is said to be clinically normal. Suppose TSH levels falls above 4 mU/L but
free T4 levels falls within the reference range; the state of the axis is said to be
clinically subclinical hypothyroidism. Suppose TSH levels are above 4 mU/L and
free T4 levels below 7 pg/mL; the state of the axis is said to be clinically hypothy-
roidism (an underactive thyroid gland). Keeping free T4 levels within the normal
reference range is very important [3]. Lower levels of free T4 can cause hypothy-
roidism that results in several health problems including obesity, joint pain, infer-
tility, slow metabolism, puffy face, constipation, stiffness, dry skin, depression,
fatigue and higher heart rate [4].
Hyperthyroidism is another clinical state of the axis, in which free T4 levels stay
above 18 pg/mL while the levels of TSH stay below the reference range 0.4 mU/L
[5]. This state of the axis occurs when the thyroid gland over produces and secretes
the thyroid hormones either in response to chronic TSH stimulation or due to
Graves’ disease. Transient hyperthyroidism is a phenomenon that refers to the
leakage of stored thyroid hormones from the gland, typically called Hashitoxicosis
or thyroid burst [6]. It happens due to the Hashimoto’s autoimmune thyroiditis. The
bursting of thyroid gland can happen at any clinical stage of the patients.
Hashimoto’s autoimmune thyroiditis is one of the immune disorders hosted by
the thyroid gland [6, 7]. Under this disease process, the thyroid follicular tissue
undergoes the slow destruction by the immune system and thereby the thyroid
struggles to produce enough hormones for the body’s requirement. Currently, the
incidence rate of Hashimoto’s autoimmune thyroiditis is estimated to be 300–500
cases per 100,000 individuals per year. In this disease, the interaction of the
immune system with the thyroid is highly complex involving the cellular and
humoral mechanisms. The involvement of humoral mechanism can be verified
Figure 1.
The pituitary-thyroid axis is shown in this picture. It is commonly referred as a negative-feedback control.
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through a simple blood test for anti-thyroid antibody biomarkers. More specifically,
the elevated titers of anti-thyroid antibodies, thyroid peroxidase antibodies
(TPOAb) and/or thyroglobulin antibodies (TGAb) may indicate the malfunction of
the immune system [8]. For simplicity in patient-specific modeling, we choose
TPOAb as a biomarker representing the presence of the Hashimoto’s autoimmune
thyroiditis.
In 1912, Hakaru Hashimoto published the description of four cases of diffused
goiter which were showing the signs of infiltration of immune cells and antibodies
in the thyroid gland [9]. All these goiters appeared differently from the colloid
goiters that occur due to insufficient iodine in-take from the diet. In his time, the
idea of autoimmune disease had not been established in the medical literature. He
isolated these cases and asked the future clinicians to explore the mechanism of this
new form of goiter [10, 11]. In 1936, the description of goiter due to lymphocytic
thyroiditis was rediscovered in the United States and was labeled as Hashimoto’s
thyroiditis. It has been characterized as an organ-specific autoimmune disease and
swelling might be the result of the chronic stimulation of the thyroid gland by the
serum TSH [12, 13]. Now, scientists have described autoimmune thyroiditis with
atrophy, a variance from the original description of Hakaru Hashimoto.
The pituitary gland has no clue about the undergoing immune process in the
thyroid gland and does not know how to adapt to the changing environment and the
abnormal function of the thyroid [14, 15]. It simply tells the thyroid to keep up with
the release of thyroid hormones for its signal. By responding through bulging its
size, the poor thyroid gland needs to accomplish the task of producing enough levels
of hormones if it could. What initiates the immune process against the thyroid
gland? The answer is still largely unknown to the researchers, but they all speculate
the immune process might be initiated through a complex combination of the
genetic and environmental pollution [15]. Herein, we care about the functional size
of thyroid gland as opposed to the exact size of the thyroid gland, which is treated as
a hidden compartment [16]. The exact size of the thyroid gland includes the size of
the parathyroid glands, the isthmus, capillaries, blood flow and so on whereas the
functional size includes the follicular cells that contains thyroglobulin molecules in
which hormones are stored. Basically, the functional size of the gland counts the
part of the gland that is able to make and secrete hormones; obviously this infor-
mation is not available in the clinical setting.
A measurement of TPOAb titers is required from the blood test to diagnose
autoimmune thyroiditis and afterward, TPOAb titers is not usually measured as its
levels not helpful in the treatment. As mentioned above, the axis function is deter-
mined from one-time measurement of TSH and free T4, respectively. However, the
functional size of the thyroid gland cannot be measured through the laboratory
experiments or with any medical tools, which does not exist in practice at least so
far. Even if it exists, then it would be very expensive in terms of cost and time.
However, the mathematical model can help by telling us the functional size from
the clinical measurements of specific patient and from the physiological point of
view. Moreover, the functional size of the gland is different for everyone, such as
boy’s thyroid size versus men’s thyroid size or girl’s thyroid size versus women’s
thyroid size and so on. Using the model and the clinical measurements of TSH and
free T4, we will determine the initial functional size of the gland for a given patient.
Goiter due to this disease occurs more frequently in women than men [17]. Using
the model, we describe the diffused goiter as the functional size increases to keep up
with the normal production of hormones.
In reality, it is hard to perform experiments on patients in the laboratory setting
and collect data to understand the underlying dynamics of the pituitary-thyroid axis
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in autoimmune problem. Hypothetically speaking, if the experiment is possible,
then one needs to consider patients’ time, cost, safety, and variability. Two patients
with similar characteristics from societies might react to an experiment in an
unusual way [18, 19]. The inter and intra variability among patients causes a major
problem for treatment and challenges the obtained information from labs. Using the
model, we can carry out an experiment for a specific patient and the hidden
dynamics of the axis can be investigated at the microscopic level for shorter or
longer time-period. In general, the model is implemented through a computer
program and the parameters are tuned to a specific patient and then the experi-
ments can be performed with the test hypothesis [20]. Also, we can identify sensi-
tive and insensitive parameters that are responsible for the physiology of the axis
under autoimmune thyroiditis, that causes the hypothyroidism and goiter. This is
an effective and modern way to explore the complex interaction of the immune
system to the thyroid and its consequence on the negative feedback loop [21, 22].
The hormone TSH has a half-life of 1 hour in serum on the average scale.
Similarly, the hormone free T4 has a half-life of 7 days in serum on average, the
thyroid per-oxidase antibodies (TPOAb) has a half-life of 24 hours in serum on
average and the half-life of functional size of the thyroid gland is not known and
probably varies among individuals. Several time scales have been involved in the
disease process. Based on the fundamental principle of rate laws, the model will be
developed here to predict the history of patient-specific dynamics of the axis and
thyroid size in autoimmune thyroiditis [23–25]. The model can unfold the conse-
quences of the presence of antibodies titers in the blood. Basically, it can replace
humans but mimics the system that provides convenience and flexibility for
scientists to run experiments on the computer. Information obtained through the
dynamics might be useful in treating patients and improving the accuracy of the
levothyroxine treatment [26]. For instance, the levothyroxine drug can be targeted
and administered to the specific patient so that the levels of TSH and free T4
maintained within the normal reference range, which in turn can avoid other health
problems.
The remaining of this chapter is divided into three main sections. Section 2
introduces the development and construction of a coupled model describing the
interactions of two subsystems (the axis and humoral immune system) and reduces
the coupled model based on the physiological assumptions. Section 3 analyzes the
solutions of the reduced model qualitatively and numerically for various parameter
values. Section 4 describes the case studies of three patients, validity of the model
and provides the conclusion of this work.
2. Model outline
The model is constructed as a system of four ordinary differential equations
based on the following known physiological assumptions [20, 21].
2.1 Assumptions
1.The pituitary gland is diseased free, so the feed forward loop is intact.
2.Total TSH receptors concentration does not change during Hashimoto’s
autoimmune thyroiditis.
3.Serum TSH stimulates the growth of functional thyroid and the production
and secretion of thyroid hormones.
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4.The humoral immune system uses serum TPOAb to attack the thyroid and
those titers can be used as a biomarker for the level of the anti-thyroid immune
activity.
5.The patient does not demonstrate central or peripheral resistance to thyroid
hormone.
6.Serum free T4 have much slower dynamics in the disease process compared to
serum TSH, serum TPOAb and the functional size of the gland.
We denote x tð Þ, y tð Þ and w tð Þ to represent the concentrations of serum TSH
(mU/L), serum free T4 (pg/mL) and serum TPOAb (U/mL), respectively. We let
z tð Þ represent the functional size of the gland. According to the fundamental prin-
ciple of rate laws, the rate of change of concentration of TSH over time t is the
secretion rate from the pituitary gland minus the elimination rate of TSH via kidney
through the unspecified mechanism. The rate of change of concentration of free T4
over time t is the secretion rate of free T4 from the thyroid minus the elimination
rate of free T4 via kidney through unspecified mechanism. Similarly, the rate of
change of concentration of TPOAb over time t is the production rate due to the
abnormal interaction thyroid gland and immune system minus the elimination rate
of TPOAb via kidney through unspecified mechanism. Finally, the rate of change of
the functional size of thyroid gland over time t is the growth rate minus the
destruction rate of the gland.
Next, we write a coupled model that represents the interaction of two
subsystems: the negative feedback loop and the humoral immune system.
dx
dt
¼ k1 
k1y tð Þ
ka þ y tð Þ
 k2x tð Þ, x 0ð Þ ¼ x0 (1)
dy
dt
¼
k3z tð Þx tð Þ
kd þ x tð Þ
 k4y tð Þ, y 0ð Þ ¼ y0 (2)
dz
dt
¼ k5
x tð Þ
z tð Þ
N
 
 k6z tð Þw tð Þ z 0ð Þ ¼ z0 (3)
dw
dt
¼ k7z tð Þw tð Þ  k8w tð Þ w 0ð Þ ¼ w0 (4)
where x tð Þ≥0, y tð Þ≥0, z tð Þ>0 and w tð Þ≥0. The normal average value for each
state variable is given in Table 1. The model has 11 positive parameters unchanged
over time, in which each parameter has a unique physiological meaning and their
corresponding values listed in Table 2. The model (1)–(4) captured the dynamics of
two subsystems coupled through the functional size of the thyroid gland. Using
assumption (8) that serum free T4 has much slower dynamics compared to serum
Name Normal value Normal range Source Unit
x tð Þ 1 0:4 2:5 4ð Þ Literature [2] mU/L
y tð Þ 13 7  18 Literature [2] pg/mL
z tð Þ 0.015 0:005 0:125 Literature [16] L
w tð Þ 0 0 < 200 Dataset U/mL
Table 1.
Variable names, normal values, ranges, sources and units.
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TSH, serum TPOAb and the functional size of the thyroid gland, we can take
dy=dt ¼ 0 and obtain a reduced model consisting of three differential equations and
one algebraic equation:
dx
dt
¼
k1k4ka kd þ x tð Þð Þ
k4kakd þ k4kax tð Þ þ k3z tð Þx tð Þ
 k2x tð Þ, x 0ð Þ ¼ x0 (5)
z ¼
k4y kd þ xð Þ
k3x
¼ f x, yð Þ (6)
Using (Eq. (6)), the functional size can be determined for patients if a result
of TSH (x) and free T4 (y) value is known from the blood test, which in turn can
be used as an initial condition on (Eq. (3)) for the model simulation. The graph
of (Eq. (6)) is shown on the Figure 2, which illustrates the functional size
of thyroid gland in terms of varying TSH and free T4 values. Using the reduced
Name Normal value Normal range Source Unit
k1 5000 >4000 Literature [27] mU/L day
k2 16:6 N/A Literature [3] 1/day
k3 90:11 4 257 Simulation Pg/mL L day
k4 0:099021 N/A Literature [3] 1/day
k5 1 N/A Simulation L3/mU day
k6 1 N/A Simulation mL/U day
k8 0.035 N/A Literature [28] 1/day
ka 0:043 0:02 0:06 Calculation pg/mL
kd 0:05 N/A Simulation mU/L2
Table 2.
Parameter names, normal values, ranges, sources and units.
Figure 2.
The functional size of the thyroid gland can be calculated from the graph of this function of TSH and
free T4.
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model, we can describe the clinical progression of overt hypothyroidism and
thyroid size such as goiter and atrophy.
3. Model analysis
As a first step in the process of analyzing the model, we solve for steady states of
the reduced model (Eqs. (3)–(5)) from the following equations:
k1k4ka kd þ xð Þ
k4kakd þ k4kaxþ k3zx
 k2x ¼ 0
k5
x
z
N
 
 k6zw ¼ 0
k7zw k8w ¼ 0
which leads to diseased-free and diseased steady state solutions besides the
initial condition. The first steady state (diseased-free) denoted as z1,w1, x1ð Þ where
z1 ¼ x1=N,w1 ¼ 0 and the value of x1 is given by the cubic equation:
a1x1
3 þ a2x1
2 þ a3x1 þ a4 ¼ 0 (7)
where
a1 ¼
k2k3
N
>0
a2 ¼ k2k4ka >0
a3 ¼ k4ka kdk2  k1ð Þ<0 since k1 > kdk2
a4 ¼ k4kak1kd <0
By Descarte’s rule of signs, Eq. (7) has one positive real solution, so the reduced
model has diseased-free state in the positive octant for the system parameters. In
fact, this steady state solution lives on the surface of the function z ¼ f x, yð Þ given
by Eq. (6). The operation of the pituitary-thyroid axis is healthy and fully func-
tional in the presence of diseased-free steady state solution.
Next, the second steady state is the diseased state solution denoted as z2,w2, x2ð Þ
where
z2 ¼
k8
k7
w2 ¼
k7k5
k6k8
k7x2
k8
N
 
and the value x2 is given by the quadratic equation:
b1x2
2 þ b2x2 þ b3 ¼ 0 (8)
where
b1 ¼ k2k4ka þ
k2k3k8
k7
 
>0
b2 ¼ k4ka kdk2  k1ð Þ<0 since k1 > kdk2
7
Mathematical Modeling of Thyroid Size and Hypothyroidism in Hashimoto’s Thyroiditis
DOI: http://dx.doi.org/10.5772/intechopen.90481
b3 ¼ k4kak1kd <0
By Descarte’s rule of signs, Eq. (8) has one positive real solution when x2 >
Nk8
k7
so
the reduced model has diseased state in the positive octant for the system
parameters.
Remark:When N ¼ k7x2=k8, the second steady state (diseased state) of the
system (Eqs. (3)–(5)) has w2 ¼ 0. So, it must coincide with the first steady state
(diseased-free state) in the positive quadrant if
N ¼
k7x2
k8
¼
k7x1
k8
3.1 Definition: bifurcation parameter
We let N be the unique value of N, where
N ¼
k7x0
k8
¼
k7x2
k8
¼
k7x1
k8
the system undergoes a bifurcation. We call N is a bifurcation value of the
system (Eqs. (3)–(5)) and N is the bifurcation parameter. We can take the initial
state of the system at where the diseased-free and diseased steady states merge
together. Using this definition, we can also calculate the parameter k7 (say k7
)
provided the values of k8 and x0 is known.
3.2 Equation of tangent plane
We first define the level surface (S) through a function of three variables from
Eq. (6) as
g x tð Þ, y tð Þ, z tð Þð Þ ¼
k4y tð Þ kd þ x tð Þð Þ
k3x tð Þ
 z tð Þ ¼ 0 (9)
The normal surface vector n
!
can be calculated from the gradient of this function
n
!
¼ ⟨
∂g
∂x
,
∂g
∂y
,
∂g
∂z
⟩
In particular, the normal vector of the surface S at initial state P x0, y0, z0
 
is a
vector perpendicular to the tangent plane of S at P is given by
n
!
¼ ⟨
k4kdy0
k3x02
,
k4kd
k3x0
þ
k4
k3
 
,1⟩
The equation of the tangent plane at point P x0, y0, z0
 
is given by
axþ byþ cz ¼ d
where
a ¼
k4kdy0
k3x02
, b ¼
k4kd
k3x0
þ
k4
k3
 
, c ¼ 1∧
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d ¼ ax0 þ by0 þ cz0
Next, we take the implicit differentiation of Eq. (9) with respect to time t and
substituting the initial point P x0, y0, z0,w0
 
, which results in the following equa-
tion for N:
∂g
∂x
∙
dx
dt
þ
∂g
∂y
∙
dy
dt
þ
∂g
∂z
∙
dz
dt
 
P
¼ 0
N ¼
k4y0 k1kakd  x0 k2kd þ k4 kd þ x0ð Þð Þ ka þ y0
  
k5k3x20 ka þ y0
  þ x0
z0

k4 þ k6w0ð Þz0
k5
(10)
Notice that N is independent of the parameters k7 and k8. So, we can use this
value of N as N. This threshold value can be uniquely determined for every patient
based on their initial blood test results and if we know other parameters k1, k2, k3, k4,
k5, k6, ka and kd. We have estimated the values of all other parameters from the
literature or through calculation (see Table 2).
3.3 Linear stability
As the bifurcation parameter N varies from the threshold value N ¼ k7x0=k8,
the number of the steady states changes, and its behavior near the steady states
(linear stability) changes as well. Moreover, as the bifurcation parameter varies, the
appearance and disappearance of steady states can be seen on the tangent plane at
the initial state of the function z ¼ f x, yð Þ. For this system (Eqs. (3)–(5)), there are
three cases, namely when N <N, N ¼ N and N >N. Figure 3 illustrates a nice
overview of how the solutions become stable and unstable as parameter N changes
from 0 to 300.
Case 1: N <N
When N <N, the system (Eqs. (3)–(5)) has two steady states, which undergoes
a saddle-node bifurcation—disappearance of the saddle diseased state. One can
Figure 3.
The bifurcation diagram shows the steady state values of TSH as the parameter N varies from 0 to 300. BP
means the branch or bifurcation point where another equilibrium curve passes through and the system switches
its stability. The parameter value of N at BP is 66.7. H is a neutral saddle, but not the bifurcation point for the
equilibrium curve. At H, there is a homoclinic orbit for the system.
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imagine if we start the system from the initial steady state, which splits into the
diseased-free and diseased state. The disease state is asymptotically stable which
means all its eigenvalues are purely negative real. However, the diseased-free state
is saddle because two of its eigenvalues are positive real and one of its eigenvalues is
a negative real. See [22] for proof of the stability of the diseased-free and diseased
steady state.
As the value of N decreases from the threshold value and when it is close to zero,
there exists a homoclinic orbit associated at the initial state which forms the
boundary for the asymptomatically stable interior diseased state. The orbit captures
the hidden dynamics of the diffused goiter and hashitoxicosis (see Figures 4 and 5).
Case 2: N ¼ N
When N ¼ N, the system (Eqs. (3)–(5)) has one steady state (diseased-free),
which is asymptotically stable. Since there is only one steady state in the system, the
operation of the pituitary-thyroid axis in the presence of anti-thyroid peroxidase
Figure 4.
When the value of N = 10 and k7 ¼ 2:3345, the hidden dynamics of the axis and the thyroid size reveal
hashitoxicosis and goiter. The model simulation is performed for 2 years from the initial state: TSH = 1 mU/L,
free T4 = 13 pg/mL, and thyroid size = 0.015 mL and TPOAb = 10 U/mL.
Figure 5.
When N = 0.01 and k7 ¼ 2:3345, the hidden dynamics of the thyroid size capture the development of goiter and
return to normal size.
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antibodies can be tested. The numerical simulation of the model shows TPOAb
slowly approaches zero as time increases over months (see Figure 6).
Case 3: N >N
When N >N, the system (Eqs. (3)–(5)) has one steady state (diseased-free),
which is asymptotically stable. As the value of N increases beyond the threshold
value, the diseased free state is moving on the function z ¼ f x, yð Þ describing the
progression of thyroid size and the function of the axis. One can imagine if we start
the system from the initial state of normal thyroid size, then the system may
approach goiter or atrophy depending upon the parameter value of N while keeping
other parameters fixed. On the other hand, varying the parameter k7, the clinical
Figure 6.
The parameter value is set to N ¼ 66:7, k7 ¼ 2:3345 and the initial state is at euthyroidism (1, 0.015, 10).
The levels of anti-thyroid peroxidase decrease slowly whereas TSH and the functional thyroid size remains
unchanged over time, which indicates the normal operation of the axis with fully functional thyroid size.
Figure 7.
Clinical progression from euthyroidism to mild subclinical hypothyroidism when N ¼ 80, k7 ¼ 2:3345 with
initial state (1, 0.015, 10).
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mechanisms euthyroidism! subclinical hypothyroidism! overt hypothyroidism
can be explained while keeping N fixed [20]. See Figure 7 that shows the clinical
progression of subclinical hypothyroidism and thyroid size.
3.4 Exploration of parameter curve
Suppose that an individual is diagnosed with Hashimoto’s autoimmune thyroid-
itis; we can use the reduced model to explain the physical and clinical symptoms
occurring for this individual in the course of this disease. Having this disease means
everyone has a unique behavior and knowing that may be very helpful in managing
the course. In fact, certain parameter values in the reduced model are responsible
for the uniqueness in patient behavior. More specifically, we have identified
through the stability analysis that the parameter N can explain the size of the
thyroid (goiter, normal or atrophy) whereas k7 can explain the clinical progression
of the disease [21, 22]. Putting these two parameters together, one can test the
hypothesis on the patients’ symptoms. See Figure 8 that shows the parameter curve
in terms of N and k7 that is responsible for different thyroid size and clinical
conditions.
Suppose a patient’s information is given; then a threshold k7,N

 
can be
found for the patient using Eq. (10) and the definition of the bifurcation
parameter. If another information is available in the future, then another threshold
can be obtained. To be exact, the threshold is an ordered pair found on the curve
given by the bifurcation definition of parameter (see Figure 8). To simulate phys-
ical and clinical symptoms, we take two test ordered pairs from the parameter curve
below and above the threshold k7,N

 
¼ 2:3345, 66:7) while other parameters
came from Table 2. With the first test point for k7,Nð Þ ¼ 0:9904, 12:65ð Þ, we
simulated the model for a day and found the symptoms of the disease are
hashitoxicosis and goiter (see Figure 9). Similarly, by keeping the second test point
as (5.8, 397.9), the one-day simulation showed mild atrophy and overt hypothy-
roidism (see Figure 10). Finally, by keeping the third test point away from the
curve as (4.5, 150), the one-day simulation showed subclinical hypothyroidism and
normal size of the thyroid (Figure 11).
Figure 8.
The sample parameter curve of a Hashimoto’s patient is shown here. The hypothesis testing can be done for
different k7 and N values from the curve.
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4. Case studies of three patients
Using patients’ information from the peer-reviewed published article, we will
predict patients’ natural history of the disease. More precisely, the reduced model
can describe thyroid size and clinical progression from euthyroidism to subclinical
or overt hypothyroidism for each patient given below. These patients’ information
was provided by Salvatore Benvenga originally and were already published in the
article [21]. The data consists of TSH, free T4 and TPOAb information whose
normal reference ranges are (0.4–2.5) mU/L, (7–18) pg./mL and (0–200) U/mL,
respectively. Using Eq. (6) and data, we have computed the functional size of the
Figure 10.
The result of physical and clinical symptoms is mild atrophy and overt hypothyroidism, when test values
N ¼ 397:9 and k7 ¼ 5:8 are taken from the curve.
Figure 9.
The result of physical and clinical symptoms is goiter and hashitoxicosis when test values N ¼ 12:65 and k7 ¼
0:9904 are taken from the parameter curve.
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Time
(months)
TSH
(mU/L)
FT4
(pg/mL)
TPOAb
(U/mL)
Thyroid size
(mL)
N
∗
k7
∗
0 0.8282 13.5 50 15.73 51.865 2.1918
8 0.93 13 55 15.1 60.952 2.2939
30 1.178 11.8 159 13.5 84.998 2.5254
Table 3.
Patient 1 information.
Time
(months)
TSH
(mU/L)
FT4
(pg/mL)
TPOAb
(U/mL)
Thyroid size
(mL)
N
∗
k7
∗
0 1.46 15.16 164 17.23 81.908 1.9635
2 1.56 13.74 153 15.58 97.724 2.1925
3 1.85 13.09 191 14.77 122.4 2.3157
5 2.06 11.67 482 13.14 150.5 2.557
22 4.61 10.47 773 11.63 387.39 2.9411
39 5.04 7.63 537 8.467 590.65 4.1018
Table 5.
Patient 3 information.
Time
(months)
TSH
(mU/L)
FT4
(pg/mL)
TPOAb
(U/mL)
Thyroid size
(mL)
N
∗
k7
∗
0 1.54 11.78 3810 13.37 64.301 1.4614
31 1.57 12.36 1310 14.02 93.662 2.088
39 1.54 11.97 1480 13.58 93.294 2.1203
Table 4.
Patient 2 information.
Figure 11.
The result of physical and clinical symptoms are normal thyroid size and subclinical hypothyroidism, when test
values of N ¼ 4:5 and k7 ¼ 150 are not taken from the curve.
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thyroid gland. Using Eq. (10), data and the bifurcation definition, we have
computed N and k7 for all patients given below (see Tables 3–5).
Assuming all patients had diseased-free state (1, 13, 0.015, 0) at some point, the
data provides us the diseased state from which one can back trace the physical and
clinical conditions caused by the disease and experienced by the patients. We have
taken three untreated patients with a known biomarker for the presence of the
autoimmune thyroiditis. Patients 1 and 2 visited the clinic three times whereas
patient 3 visited the clinic six times due to mild goiter or other symptoms. We do
not have any information about their thyroid sizes in the data.
In Table 3, the clinical measurements, the functional thyroid size and parame-
ters are listed for patient 1 which form the diseased states. The model simulation
started from each diseased state for 10 years to back trace the natural symptoms of
patient 1 due to autoimmune thyroiditis. The course of disease revealed thyroid size
changes from mild goiter to normal while the function of axis remained normal (see
Figure 12). In Table 4, the clinical measurements, the functional thyroid size and
parameters are listed for patient 2. The model simulation is done for 1 year to back
trace the symptoms from the course of the disease. The first disease course revealed
a development of subclinical hypothyroidism with normal functional thyroid size
(see Figure 13). Similarly, patient 3 diseased states are found in Table 5. The model
simulation is done only for 2 days to capture the early course of the disease.
Figure 12.
Three courses of the natural history of the disease is shown here for patient 1. Patient 1 visited the clinic three
times and was not required any treatment based on their TSH and free T4 values. The model is simulated for
10 years in which the first course of disease shows thyroid size started with mild goiter and then returned to
normal.
Figure 13.
Three courses of the disease is shown here for the second patient. This patient visited the clinic three times and
was not required treatment based on their TSH and free T4 measurements. The model is simulated for 1 year to
observe the hidden dynamics. The course of the disease showed patient had developed subclinical hypothyroidism
with normal thyroid size.
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Surprising results are seen in the early course of the disease (see Figure 14). This
patient had developed both clinical and physical symptoms at different points in
time. In particular, the first course shows mild goiter and mild hashitoxicosis
whereas the sixth course shows the overt hypothyroidism and mild atrophy.
5. Conclusion
The human body is made up of so many subsystems such as the pituitary-
thyroid axis and the immune system. These subsystems do not disrupt the function
of each other in healthy people. A function of the pituitary-thyroid axis is to secrete
the appropriate levels of thyroid hormones and take care of body’s metabolism
whereas the function of the immune system is to protect the body’s organs such as
the thyroid gland and remove foreign substances that try to invade the organs.
Hashimoto discovered the abnormal interaction of the immune system to the thy-
roid gland, which resulted in the disruption of the physiology of the axis. Later this
diseased condition has been named as Hashimoto’s autoimmune thyroiditis. Hashi-
moto noticed the destruction of thyroid follicular cells through physical and clinical
symptoms in four middle aged female patients.
A keystone of the functional thyroid gland is the follicular cells, which die due to
the aggressive and destructive attack by the immune system. Hashimoto patients
discovered the disease sometimes by themselves due to discomfort in the neck
(small goiter) or accidentally during annual checkup by the family physicians.
Consequences of Hashimoto disease can be classified into physical and clinical
symptoms at various stages of the disease. Both types of symptoms occur in a
sequential manner from one extreme to another. More precisely, the physical
symptom runs from goiter! atrophy whereas the clinical symptom runs from
hashitoxicosis! overt hypothyroidism. In order to describe these symptoms math-
ematically, we chose four state variables namely the size of functional thyroid gland
to describe the physical symptom, TSH and free T4 to describe the clinical symp-
toms and thyroid peroxidase antibodies as a representative for the presence of
Hashimoto disease. Modeling the disruption of the axis through a coupled model is
the key to unlock the hidden dynamics experienced by the patients. The hidden
dynamics can be seen in patients through physical and clinical symptoms.
Figure 14.
Six courses of the disease has been shown here for the third patient. This patient visited the clinic six times and
was not required any treatment based on their TSH and free T4 measurement. The model is intentionally
simulated for 2 days to capture the early dynamics of the patient. The model simulation shows this patient had
developed both clinical and physical symptoms at different points in time.
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The literature description of Hashimoto disease begins with a gradual swelling of
the thyroid gland and development of mild clinical condition, euthyroidism or
subclinical hypothyroidism and subsequent gradual progression of overt hypothy-
roidism. Small goiter and hashitoxicosis are the very early stages of the disease and
typically go untreated and hidden in the view of patients and physicians. Overt
hypothyroidism is the irreversible end clinical state (where levothyroxine treatment
is needed) whereas atrophy is irreversible end physical state of the disease. Basi-
cally, the mechanism involved in the progression of the disease is unique and
sequential. For instance, some patients may have the disease course of goiter and
euthyroidism, some may have goiter and the clinical progression euthyroidism!
subclinical hypothyroidism and some patients may have gradual progression from
normal thyroid size to atrophy and euthyroidism to overt hypothyroidism.
Herein, we have developed and used patient-specific model to describe all pos-
sible mechanisms involved in the autoimmune thyroiditis. This can be achieved
using two parameters N and k7. To be precise, the parameter N and k7 can trace the
thyroid size and clinical progression. We validated the model with three patients’
data by describing their natural history of the disease.
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